Evidence map›Paper›PMID 39003251›Full record

ArticleCell death & disease2024

The eEF2 kinase coordinates the DNA damage response to cisplatin by supporting p53 activation.

Jonathan K M Lim, Arash Samiei, Alberto Delaidelli, Jessica Oliveira de Santis, Vanessa Brinkmann, Christopher J Carnie, Daniel Radiloff, Laura Hruby, Alisa Kahler, Jordan Cran and 2 more

Abstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Circular RNAs modulate cancer drug resistance: advances and challenges.Cancer drug resistance (Alhambra, Calif.) · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jonathan K M Lim *Institute of Neuropathology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.ORCID 0000-0002-1798-8954
Arash Samiei *Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Alberto DelaidelliDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Jessica Oliveira de SantisDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Vanessa BrinkmannInstitute of Toxicology, Heinrich Heine University, Düsseldorf, Germany.ORCID 0000-0002-2284-3143
Christopher J CarnieDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0001-7006-5596
Daniel RadiloffDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Laura HrubyInstitute of Neuropathology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Alisa KahlerInstitute of Neuropathology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Jordan CranTerry Fox Laboratory, BC Cancer Research Institute, Vancouver, BC, Canada.ORCID 0009-0000-8674-2176
Gabriel LeprivierInstitute of Neuropathology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. gabriel.leprivier@med.uni-duesseldorf.de.ORCID 0000-0002-2299-8989
Poul H SorensenDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. psor@mail.ubc.ca.ORCID 0000-0001-7447-2199

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eukaryotic elongation factor 2 (eEF2) kinase (eEF2K) is a stress-responsive hub that inhibits the translation elongation factor eEF2, and consequently mRNA translation elongation, in response to hypoxia and nutrient deprivation. EEF2K is also involved in the response to DNA damage but its role in response to DNA crosslinks, as induced by cisplatin, is not known. Here we found that eEF2K is critical to mediate the cellular response to cisplatin. We uncovered that eEF2K deficient cells are more resistant to cisplatin treatment. Mechanistically, eEF2K deficiency blunts the activation of the DNA damage response associated ATM and ATR pathways, in turn preventing p53 activation and therefore compromising induction of cisplatin-induced apoptosis. We also report that loss of eEF2K delays the resolution of DNA damage triggered by cisplatin, suggesting that eEF2K contributes to DNA damage repair in response to cisplatin. In support of this, our data shows that eEF2K promotes the expression of the DNA repair protein ERCC1, critical for the repair of cisplatin-caused DNA damage. Finally, using Caenorhabditis elegans as an in vivo model, we find that deletion of efk-1, the worm eEF2K ortholog, mitigates the induction of germ cell death in response to cisplatin. Together, our data highlight that eEF2K represents an evolutionary conserved mediator of the DNA damage response to cisplatin which promotes p53 activation to induce cell death, or alternatively facilitates DNA repair, depending on the extent of DNA damage.

Indexed as

Caenorhabditis elegansCisplatinDNA DamageElongation Factor 2 KinaseTumor Suppressor Protein p53AnimalsApoptosisAtaxia Telangiectasia Mutated ProteinsDNA RepairHumansAtaxia Telangiectasia Mutated ProteinsCisplatinEEF2K protein, humanElongation Factor 2 KinaseTumor Suppressor Protein p53

Identifiers

PMID39003251
PMCPMC11246425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.